Literature DB >> 14688127

Urokinase-deficient mice fail to generate a type 2 immune response following schistosomal antigen challenge.

Margaret R Gyetko1, Sudha Sud, Stephen W Chensue.   

Abstract

Activated lymphocytes express urokinase-type plasminogen activator (uPA). Previous work suggests that uPA modulates T-lymphocyte responses. Mice deficient in uPA (uPA(-/-)) fail to generate type 1 (T1) immune responses during infection with Cryptococcus neoformans. Failure to generate either a T1 or a T2 immune response is not predictive of defects in the alternative response. Conversely, down-regulation of one type of immune response may result in inappropriate overactivation of the other. It is not known whether the immune defect in uPA(-/-) mice affects only T1 responses or whether T2 responses are also impaired. Impairment of both T1 and T2 responses would suggest a global T-cell defect in the absence of uPA. To determine the role of uPA in T2 immune responses, wild-type (WT) and uPA(-/-) mice were primed and challenged with schistosomal egg antigen (SEA). This elicits strong polarization to T2 immune responses in immunocompetent mice. The challenged WT mice developed delayed-type hypersensitivity (DTH) to SEA; high levels of serum immunoglobulin E (IgE); a strong T2 cytokine phenotype with markedly elevated levels of interleukin-4 (IL-4), IL-5, and IL-13; and eosinophil-rich pulmonary granulomas. uPA(-/-) mice failed to develop DTH to SEA; did not polarize Ig production to IgE; did not produce high levels of IL-4, IL-5, or IL-13; and had markedly reduced numbers of granuloma-associated eosinophils. uPA(-/-) mice fail to generate polarized T2 immune responses to a T2-inducing pathogen. These findings, in conjunction with our previous work, demonstrate that mice deficient in uPA have profoundly impaired immunity involving both T1 and T2 polarization and are largely immunologically unresponsive.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688127      PMCID: PMC343962          DOI: 10.1128/IAI.72.1.461-467.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells.

Authors:  L A Miles; E F Plow
Journal:  Thromb Haemost       Date:  1987-10-28       Impact factor: 5.249

2.  IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinophilia.

Authors:  T A Wynn; D Jankovic; S Hieny; A W Cheever; A Sher
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

3.  Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA.

Authors:  M R Gyetko; S Sud; J Sonstein; T Polak; A Sud; J L Curtis
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

4.  Profound effect of the absence of IL-4 on T cell responses during infection with Schistosoma mansoni.

Authors:  J A Pedras-Vasconcelos; L R Brunet; E J Pearce
Journal:  J Leukoc Biol       Date:  2001-11       Impact factor: 4.962

5.  Eosinophils promote allergic disease of the lung by regulating CD4(+) Th2 lymphocyte function.

Authors:  J R MacKenzie; J Mattes; L A Dent; P S Foster
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

6.  Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection.

Authors:  Margaret R Gyetko; Sudha Sud; Gwo-Hsiao Chen; Jennifer A Fuller; Stephen W Chensue; Galen B Toews
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

7.  Schistosoma-specific helper T cell clones from subjects resistant to infection by Schistosoma mansoni are Th0/2.

Authors:  P Couissinier-Paris; A J Dessein
Journal:  Eur J Immunol       Date:  1995-08       Impact factor: 5.532

8.  Early IL-4 production by non-CD4+ cells at the site of antigen deposition predicts the development of a T helper 2 cell response to Schistosoma mansoni eggs.

Authors:  E A Sabin; E J Pearce
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

9.  Interleukin-4 receptor alpha chain and STAT6 signaling inhibit gamma interferon but not Th2 cytokine expression within schistosome granulomas.

Authors:  Ahmed Metwali; Arthur Blum; David E Elliott; Joel V Weinstock
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Eosinophil recruitment in type-2 hypersensitivity pulmonary granulomas: source and contribution of monocyte chemotactic protein-3 (CCL7).

Authors:  Xiao-Zhou Shang; Bo-Chin Chiu; Valerie Stolberg; Nicholas W Lukacs; Steven L Kunkel; Hedwig S Murphy; Stephen W Chensue
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

View more
  8 in total

1.  SerpinB2 mediated regulation of macrophage function during enteric infection.

Authors:  Terez Shea-Donohue; Aiping Zhao; Toni M Antalis
Journal:  Gut Microbes       Date:  2014-02-05

2.  Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Authors:  Kerstin Göbel; Chloi-Magdalini Asaridou; Monika Merker; Susann Eichler; Alexander M Herrmann; Eva Geuß; Tobias Ruck; Lisa Schüngel; Linda Groeneweg; Venu Narayanan; Tilman Schneider-Hohendorf; Catharina C Gross; Heinz Wiendl; Beate E Kehrel; Christoph Kleinschnitz; Sven G Meuth
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

3.  4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.

Authors:  Sachin Yende; Derek C Angus; Jingzhong Ding; Anne B Newman; John A Kellum; Rongling Li; Robert E Ferrell; Joseph Zmuda; Stephen B Kritchevsky; Tamara B Harris; Melissa Garcia; Kristine Yaffe; Richard G Wunderink
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

4.  Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.

Authors:  Sherry Thornton; Harini Raghu; Carolina Cruz; Malinda D Frederick; Joseph S Palumbo; Eric S Mullins; Kasper Almholt; Pernille A Usher; Matthew J Flick
Journal:  Blood Adv       Date:  2017-03-21

5.  The mannose 6-phosphate/insulin-like growth factor 2 receptor mediates plasminogen-induced efferocytosis.

Authors:  Anna Ohradanova-Repic; Christian Machacek; Clemens Donner; Vanessa Mühlgrabner; Eva Petrovčíková; Alexandra Zahradníková; Kristína Vičíková; Václav Hořejší; Hannes Stockinger; Vladimir Leksa
Journal:  J Leukoc Biol       Date:  2019-01-18       Impact factor: 4.962

6.  Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.

Authors:  Elisavet Karamanavi; Katerina Angelopoulou; Sophia Lavrentiadou; Anastasia Tsingotjidou; Zaphiris Abas; Ioannis Taitzoglou; Ioannis Vlemmas; Suzan E Erdman; Theofilos Poutahidis
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

7.  Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells.

Authors:  Kerstin Göbel; Susann Pankratz; Chloi-Magdalini Asaridou; Alexander M Herrmann; Stefan Bittner; Monika Merker; Tobias Ruck; Sarah Glumm; Friederike Langhauser; Peter Kraft; Thorsten F Krug; Johanna Breuer; Martin Herold; Catharina C Gross; Denise Beckmann; Adelheid Korb-Pap; Michael K Schuhmann; Stefanie Kuerten; Ioannis Mitroulis; Clemens Ruppert; Marc W Nolte; Con Panousis; Luisa Klotz; Beate Kehrel; Thomas Korn; Harald F Langer; Thomas Pap; Bernhard Nieswandt; Heinz Wiendl; Triantafyllos Chavakis; Christoph Kleinschnitz; Sven G Meuth
Journal:  Nat Commun       Date:  2016-05-18       Impact factor: 14.919

Review 8.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.